Eflornithine
- Generic Name
- Eflornithine
- Brand Names
- Vaniqa
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12F2N2O2
- CAS Number
- 70052-12-9
- Unique Ingredient Identifier
- ZQN1G5V6SR
- Background
Eflornithine is a prescription drug indicated in the treatment of facial hirsutism (excessive hair growth). Eflornithine hydrochloride cream for topical application is intended for use in women suffering from facial hirsutism and is sold by Allergan, Inc. under the brand name Vaniqa. Eflornithine for injection against sleeping sickness was manufactured by Sanofi Aventis and sold under the brand name Ornidyl in the USA. It is now discontinued. Eflornithine is on the World Health Organization's List of Essential Medicines.
- Indication
Eflornithine is indicated in the treatment of facial hirsutism (excessive hair growth).
- Associated Conditions
- Meningoencephalitic stage Trypanosoma brucei gambiense infection
- Associated Therapies
- Hair removal therapy
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
- Conditions
- Adenomatous Polyp
- Interventions
- Drug: AspirinDrug: EflornithineOther: PlaceboOther: Laboratory Biomarker AnalysisOther: Telephone-Based Intervention
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 107
- Registration Number
- NCT00983580
- Locations
- 🇺🇸
University of Illinois College of Medicine - Chicago, Chicago, Illinois, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
- Conditions
- Precancerous Condition
- Interventions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 375
- Registration Number
- NCT00118365
- Locations
- 🇺🇸
University of California Medical Center At Irvine-Orange Campus, Orange, California, United States
Eflornithine in Treating Patients With Bladder Cancer
- Conditions
- Bladder Cancer
- First Posted Date
- 2004-02-20
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 450
- Registration Number
- NCT00003814
- Locations
- 🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸Piedmont Urology PC, Atlanta, Georgia, United States
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
- Conditions
- Colorectal CancerFamilial Adenomatous Polyposis
- Interventions
- Drug: CelecoxibOther: PlaceboDrug: eflornithineOther: Laboratory biomarker analysisOther: Questionnaire administration
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 205
- Registration Number
- NCT00033371
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.